Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Net Margin (2020 - 2025)

Rani Therapeutics Holdings has reported Net Margin over the past 5 years, most recently at 581.66% for Q4 2025.

  • Quarterly results put Net Margin at 581.66% for Q4 2025, up 94772.0% from a year ago — trailing twelve months through Dec 2025 was 2472.38% (up 303190.0% YoY), and the annual figure for FY2025 was 2472.38%, up 303190.0%.
  • Net Margin for Q4 2025 was 581.66% at Rani Therapeutics Holdings, up from 7405.81% in the prior quarter.
  • Over the last five years, Net Margin for RANI hit a ceiling of 1474.25% in Q2 2023 and a floor of 7405.81% in Q1 2025.
  • Median Net Margin over the past 4 years was 279.7% (2021), compared with a mean of 576.75%.
  • Biggest five-year swings in Net Margin: surged 424363bps in 2021 and later crashed -261387bps in 2024.
  • Rani Therapeutics Holdings' Net Margin stood at 279.7% in 2021, then skyrocketed by 488bps to 1084.49% in 2023, then crashed by -241bps to 1529.38% in 2024, then skyrocketed by 62bps to 581.66% in 2025.
  • The last three reported values for Net Margin were 581.66% (Q4 2025), 7405.81% (Q1 2025), and 1529.38% (Q4 2024) per Business Quant data.